Things
IPCEI Salute 1 supports research, innovation and the first industrial application of healthcare products, as well as innovative drug production processes. IPCEI Med4Cure covers research and development projects covering all key stages of the pharmaceutical value chain, from the collection and study of cells, tissues and other samples, to sustainable manufacturing technologies for innovative therapies, including personalized treatments, and to the application of advanced digital technologies. The project aims to accelerate medical progress and promote the resilience of the EU healthcare industry by improving drug discovery, in particular for unmet medical needs such as rare diseases, and by developing innovative and more sustainable production processes for medicines. These developments will improve the quality of healthcare and increase the EU's preparedness for emerging health threats, while contributing to the green transition.
Who is it aimed at?
The beneficiaries of the benefits are: • companies authorized by the European Commission Decision C(2024) 3629 final of 28 May 2024; • additional subjects admitted on a specific invitation to express interest from the Ministry, subject to expression, notification and subsequent authorization by the European Commission in compliance with the relevant Decision.
What does it predict
Granting of Fund benefits to entities implementing the project, authorized pursuant to European Commission Decision C(2024) 3629 final of 28 May 2024.
